The White House has invoked（援用） the Defense Production Act to help Pfizer Inc ramp up（產能提升） COVID-19 vaccine production and that 「every option」 was on the table to produce more Johnson & Johnson vaccine should it be authorized.
Pfizer Inc：輝瑞公司，是一家總部位於美國紐約的跨國製藥公司，研發總部位於康乃狄克州的格羅頓市。根據收入排名，輝瑞是全球最大的製藥公司。Johnson & Johnson ：強生公司是一家美國醫療保健產品、醫療器材及藥廠的製造商，全球總部位於美國新澤西州的新布朗斯維克。強生集團由全球超過250家的子公司組成，其產品銷售遍及170多個國家。It will also use the wartime powers to increase at-home COVID-19 tests, and make more surgical （外科的）gloves in the United States, officials said at a Friday media briefing.
「As is the case with other vaccines, we have not found that the level of manufacturing allows us to have as much vaccine as we think we need coming out of the gate,」 said Andy Slavitt, senior adviser to the White House’s COVID-19 response team, referring to the J&J vaccine.
J&J applied on Thursday for U.S. emergency use authorization. It expects to have some vaccine ready for distribution as soon as authorized but has not said how much.
Emergent Biosolutions』 Chief Executive Robert Kramer said in an interview on Friday that the company currently is making bulk（大部分） drug substance for J&J 「at large scale.」 Emergent is only producing bulk vaccine, which is then filled into syringes （耳咽管）or vials（小瓶） and packaged for shipment by another contractor（承包商）.
Emergent BioSolutions Inc.是一家美國跨國專業生物製藥公司，總部位於馬裡蘭州的蓋瑟斯堡。它開發用於傳染病，阿片類藥物過量的疫苗和抗體治療劑，並提供用於生物防衛目的的醫療設備。Kramer said they were on track to make enough product for hundreds of millions of doses a year. It remains unclear what other supply bottlenecks may be. Kramer said his company had already benefited from the Defense Production Act under the Trump Administration, which helped the company get to the point where it’s ready to go.
Under the authority of the Defense Production Act, the government will give priority ratings to two components important to Pfizer’s vaccine production - filling pumps （灌注泵）and tangential （切線的）flow filtration （過濾）units, the officials said.
「We told you that when we heard of a bottleneck on needed equipment, supplies, or technology related to vaccine supply that we would step in and help, and we were doing just that,」 said Tim Manning, the supply chain coordinator（協調者） for the national COVID-19 response.
The government will also invoke（調用） its powers under the Defense Production Act to increase at-home COVID-19 tests with six, unnamed manufacturers, aiming to produce 61 million tests by the summer, Manning said.
It will also invoke its powers to increase the nation’s supply of surgical gloves, which are made almost exclusively overseas.